This Article Full Text Full Text (PDF) All Versions of this Article: 19/7/1803    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Charrel-Dennis, M. Articles by Lund, T. Search for Related Content PubMed PubMed Citation Articles by Charrel-Dennis, M. Articles by Lund, T.

The Human Chorionic Gonadotropin-ß Arginine⁶⁸ to Glutamic Acid Substitution Fixes the Conformation of the C-Terminal Peptide

Department of Immunology and Molecular Pathology (M.C.-D., N.T., J.D.M., P.K., I.M.R., P.J.D., T.L.), University College London, London W1T 4JF, United Kingdom; School of Biosciences (N.T.), University of East London, London E15 4LZ, United Kingdom; Department of Molecular Biology (P.M.M., J.J.), University of Aarhus, DK-8000 Aarhus, Denmark; Institute for Biomedical Aging Research (P.B.), Austrian Academy of Sciences, A-6020 Innsbruck, Austria; Chemistry Department (A.L.), University of Glasgow, Glasgow GI2 8QQ, Scotland, United Kingdom; and Department of Oral Immunology (C.K.), Kings College London, London SE1 9RT, United Kingdom

Address all correspondence and requests for reprints to: Dr. Torben Lund, Department of Immunology and Molecular Pathology, University College London, 46 Cleveland Street, London W1T 4JF, United Kingdom. E-mail: t.lund{at}ucl.ac.uk.

Wild-type human chorionic gonadotropin (hCG) has been used as a contraceptive vaccine. However, extensive sequence homology with LH elicits production of cross-reactive antibodies. Substitution of arginine⁶⁸ of the ß-subunit (hCGß) with glutamic acid (R68E) profoundly reduces the cross-reactivity while refocusing the immune response to the hCGß-specific C-terminal peptide (CTP). To investigate the molecular basis for this change in epitope usage, we immunized mice with a plasmid encoding a truncated hCGß-R68E chain lacking the CTP. The animals produced LH-cross-reactive antibodies, suggesting that the refocused immunogenicity of R68E is a consequence of epitope masking by a novel disposition of the CTP in the mutant rather than a structural change in the cross-reactive epitope region. This explanation was strongly supported by surface plasmon resonance analysis using a panel of anti-hCGß-specific and anti-hCGß/LH cross-reactive monoclonal antibodies (mAbs). Whereas the binding of the LH cross-reactive mAbs to hCGß-R68E was eliminated, mAbs reacting with hCGß-specific epitopes bound to hCGß and hCGß-R68E with identical affinities. In a separate series of experiments, we observed that LH cross-reactive epitopes were silent after immunization with a plasmid encoding a membrane form of hCGß-R68E, as previously observed with the soluble mutant protein itself. In contrast, the plasmid encoding the soluble secreted form of hCGß-R68E evoked LH cross-reactive antibodies, albeit of relatively low titer, suggesting that the handling and processing of the proteins produced by the two constructs differed.